Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 401 - 450 av 504 resultater
Tid
Selskap
Tittel
Sektor
Kategori
21 Dec 2021
05:30 CET
SANOFI
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle
20103015 Pharmaceuticals
Mergers, Acquiqitions, Transferts
21 Dec 2021
05:30 CET
SANOFI
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
20103015 Pharmaceuticals
Mergers, Acquiqitions, Transferts
16 Dec 2021
08:00 CET
SANOFI
Communiqué de presse : Gilles SCHNEPP prend la Présidence du Comité des Nominations, de la Gouvernance et de la RSE de Sanofi
20103015 Pharmaceuticals
Other subject
16 Dec 2021
08:00 CET
SANOFI
Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
20103015 Pharmaceuticals
Other subject
15 Dec 2021
07:30 CET
SANOFI
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
20103015 Pharmaceuticals
Other subject
15 Dec 2021
07:30 CET
SANOFI
Sanofi et GSK annoncent des données préliminaires positives sur leur candidat-vaccin de rappel contre la COVID-19 et la poursuite de leur essai de phase III, sur les recommandations d’un comité de suivi indépendant
20103015 Pharmaceuticals
Other subject
14 Dec 2021
15:00 CET
SANOFI
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
20103015 Pharmaceuticals
Other subject
14 Dec 2021
15:00 CET
SANOFI
Les données de deux études de phase III montrant que le fitusiran réduit significativement les saignements chez les personnes atteintes d’hémophilie A ou B, avec ou sans inhibiteurs, ont été présentées au Congrès de l’ASH
20103015 Pharmaceuticals
Other subject
13 Dec 2021
07:00 CET
SANOFI
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
20103015 Pharmaceuticals
Other subject
13 Dec 2021
07:00 CET
SANOFI
Présentation des données positives de phase III relatives à Dupixent® (dupilumab) chez les enfants de 6 mois à 5 ans atteints de dermatite atopique modérée à sévère lors d’une séance de dernière heure du congrès RAD 2021
20103015 Pharmaceuticals
Other subject
08 Dec 2021
23:30 CET
SANOFI
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
20103015 Pharmaceuticals
Other subject
08 Dec 2021
23:30 CET
SANOFI
Le New England Journal of Medicine publie les résultats positifs de phase III de Dupixent® (dupilumab) dans le traitement de l’asthme modéré à sévère de l’enfant
20103015 Pharmaceuticals
Other subject
01 Dec 2021
20:46 CET
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - October 2021
20103015 Pharmaceuticals
Share history
01 Dec 2021
20:46 CET
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2021
20103015 Pharmaceuticals
Share history
01 Dec 2021
07:30 CET
SANOFI
Conférence investisseurs dédiée aux vaccins : Sanofi confirme ses solides perspectives de croissance et présente un portefeuille de plusieurs candidats vaccins innovants
20103015 Pharmaceuticals
Other subject
01 Dec 2021
07:30 CET
SANOFI
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
20103015 Pharmaceuticals
Other subject
01 Dec 2021
07:00 CET
SANOFI
Sanofi va acquérir Origimm Biotechnology et s’engage dans le traitement de l’acné par l’immunothérapie vaccinale
20103015 Pharmaceuticals
Other subject
01 Dec 2021
07:00 CET
SANOFI
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
20103015 Pharmaceuticals
Other subject
18 Nov 2021
07:30 CET
SANOFI
Sanofi investit 180 millions de dollars dans le capital d’Owkin pour faire progresser son portefeuille en oncologie grâce à l’intelligence artificielle et à l’apprentissage fédéré
20103015 Pharmaceuticals
Other subject
18 Nov 2021
07:30 CET
SANOFI
Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
20103015 Pharmaceuticals
Other subject
09 Nov 2021
15:05 CET
SANOFI
Sanofi completes acquisition of Kadmon
20103015 Pharmaceuticals
Other subject
09 Nov 2021
15:05 CET
SANOFI
Sanofi finalise l’acquisition de Kadmon
20103015 Pharmaceuticals
Other subject
28 Oct 2021
07:30 CEST
SANOFI
Sanofi : Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)
20103015 Pharmaceuticals
Other subject
28 Oct 2021
07:30 CEST
SANOFI
Sanofi : Forte performance au T3 2021. Croissance du BNPA des activités attendue en 2021 à environ 14% à TCC(1)
20103015 Pharmaceuticals
Other subject
27 Oct 2021
20:57 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - September 2021
20103015 Pharmaceuticals
Share history
27 Oct 2021
20:57 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Septembre 2021
20103015 Pharmaceuticals
Share history
25 Oct 2021
07:00 CEST
SANOFI
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
20103015 Pharmaceuticals
Other subject
25 Oct 2021
07:00 CEST
SANOFI
Un deuxième essai de phase III consacré à Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophiles a permis d’obtenir des améliorations significatives des signes cliniques et souligne le rôle de l’inflammation de type 2 dans
20103015 Pharmaceuticals
Other subject
22 Oct 2021
07:00 CEST
SANOFI
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
20103015 Pharmaceuticals
Other subject
22 Oct 2021
07:00 CEST
SANOFI
Dupixent® (dupilumab) – premier médicament biologique ayant permis d’obtenir une réduction significative des démangeaisons et lésions cutanées causées par le prurigo nodulaire, une maladie inflammatoire de type 2, dans le cadre d’un essai d
20103015 Pharmaceuticals
Other subject
20 Oct 2021
23:30 CEST
SANOFI
La FDA approuve l’extension des indications de Dupixent® (dupilumab) au traitement de l’asthme modéré à sévère de l’enfant de 6 à 11 ans
20103015 Pharmaceuticals
Other subject
20 Oct 2021
23:30 CEST
SANOFI
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
20103015 Pharmaceuticals
Other subject
13 Oct 2021
09:00 CEST
SANOFI
Présentation à l’ECTRIMS 2021 de nouvelles données à long terme qui confortent le profil de tolérance et d’efficacité du tolébrutinib à pénétration cérébrale
20103015 Pharmaceuticals
Other subject
13 Oct 2021
09:00 CEST
SANOFI
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
20103015 Pharmaceuticals
Other subject
01 Oct 2021
20:28 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Aout 2021
20103015 Pharmaceuticals
Share history
01 Oct 2021
20:28 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - August 2021
20103015 Pharmaceuticals
Share history
30 Sep 2021
14:30 CEST
SANOFI
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
20103015 Pharmaceuticals
Other subject
30 Sep 2021
14:30 CEST
SANOFI
Présentation à l’EADV de nouvelles données de dernière minute sur le profil clinique émergent de l’amlitélimab (anciennement KY1005), chez l’adulte atteint de dermatite atopique modérée à sévère inadéquatement contrôlée
20103015 Pharmaceuticals
Other subject
28 Sep 2021
08:00 CEST
SANOFI
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
20103015 Pharmaceuticals
Other subject
28 Sep 2021
08:00 CEST
SANOFI
Sanofi annonce des résultats intermédiaires positifs de phase I/II pour son premier candidat-vaccin à base d’ARNm
20103015 Pharmaceuticals
Other subject
24 Sep 2021
07:30 CEST
SANOFI
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
20103015 Pharmaceuticals
Other subject
24 Sep 2021
07:30 CEST
SANOFI
Sanofi : Mise en ligne du document « Q3 2021 Memorandum for modelling purposes »
20103015 Pharmaceuticals
Other subject
21 Sep 2021
07:00 CEST
SANOFI
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
20103015 Pharmaceuticals
Other subject
21 Sep 2021
07:00 CEST
SANOFI
Présentation de nouvelles données relatives à Dupixent® (dupilumab) dans le traitement de la dermatite atopique modérée à sévère de patients dès l’âge de 6 ans au WCPD et au congrès de l’EADV
20103015 Pharmaceuticals
Other subject
19 Sep 2021
17:30 CEST
SANOFI
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
20103015 Pharmaceuticals
Other subject
19 Sep 2021
17:30 CEST
SANOFI
Des données de dernière minute présentées au Congrès de l’ESMO montrent qu’un traitement de première ligne par Libtayo® (cemiplimab) en association avec une chimiothérapie améliore significativement la survie globale des patients atteints d
20103015 Pharmaceuticals
Other subject
14 Sep 2021
15:26 CEST
SANOFI
Sanofi finalise l’acquisition de Translate Bio et accélère le déploiement de la technologie de l’ARNm pour le développement de nouveaux vaccins et agents thérapeutiques
20103015 Pharmaceuticals
Other subject
14 Sep 2021
15:26 CEST
SANOFI
Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics
20103015 Pharmaceuticals
Other subject
09 Sep 2021
07:00 CEST
SANOFI
Sanofi fait le point sur l’étude de phase III consacrée au rilzabrutinib dans le traitement du pemphigus
20103015 Pharmaceuticals
Other subject
09 Sep 2021
07:00 CEST
SANOFI
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
20103015 Pharmaceuticals
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
8
9
10
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva